© Reuters.
In a series of recent developments in the biotechnology and healthcare sector, Takeda Pharmaceutical’s dengue tetravalent vaccine Qdenga has received endorsement from the World Health Organization’s advisory panel. The vaccine is set for deployment in high-risk areas among children aged six to 16 years. This news came on Wednesday, even as Takeda’s shares slipped past 1%.
In other sector news, SomaLogic and Standard BioTools have announced an all-stock merger. The announcement of the merger propelled SomaLogic’s shares 6% higher in premarket trading on Wednesday.
Meanwhile, Synlogic (NASDAQ:) has successfully closed its public offering, yielding approximately $21 million.
These events were reflected in minor oscillations in the iShares Biotechnology ETF and Health Care Select Sector SPDR Fund during premarket trading on Wednesday.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here